Kairos Pharma, Ltd. presented initial Phase 1 data on ENV105 combination therapy in non-small cell lung cancer at the World Lung Cancer Conference.
The presentation focused on the combination of Osimertinib and Carotuximab for advanced, EFGR-mutated non-small cell lung cancer patients.
The primary objective of the open-label trial is to evaluate the safety and tolerability of the combination therapy.
Lead Candidate: ENV105
ENV105 is an antibody targeting CD105, identified as a key driver of resistance to cancer treatments.
Trial Focus
The trial focuses on the combination therapy of ENV105 with Osimertinib for non-small cell lung cancer treatment.
Company Mission
Kairos Pharma aims to utilize structural biology to overcome drug resistance and immune suppression in cancer therapeutics.
- Kairos Pharma is at the forefront of oncology therapeutics, specifically targeting drug resistance.
- ENV105 aims to reverse drug resistance by targeting CD105, restoring the effectiveness of standard therapies in multiple cancer types.
Kairos Pharma's Phase 1 data presentation marks a significant step in addressing unmet medical needs in lung cancer treatment. Their innovative approach shows promise in overcoming drug resistance.